Answers are grounded in this paper and cite their sources.
BACKGROUND: The purpose of this study was to investigate whether local IL-17A neutralization attenuates peri-implant alveolar bone resorption in type 2 diabetes mellitus (T2DM) rats. METHODS: Thirty male Sprague-Dawley rats with T2DM were randomly divided into three groups (n = 10): a control group (without ligature‑induced peri‑implantitis), a peri-implantitis (PI) group, and an anti-IL-17A group. Peri-implant bone changes were evaluated by micro-CT, osteoclastogenesis by TRAP staining, and inflammatory responses by H&E staining, qPCR, immunohistochemistry, and immunofluorescence. RESULTS: Micro-CT revealed significantly greater linear and volumetric bone resorption in the PI group versus controls, which was reduced by IL-17A neutralization. TRAP staining showed increased osteoclasts in the PI group, attenuated by IL-17A neutralization. H&E staining confirmed exacerbated inflammation and bone resorption in the PI group, attenuated by anti-IL-17A. Inflammatory cytokine mRNAs were upregulated in the PI group, with IL-17A exhibiting the most pronounced increase; IL-17A neutralization reduced these levels, with IL-17A showing the greatest reduction-confirmed at the protein level. Immunofluorescence showed increased MPO+ neutrophils, IL-6+cells, and RANKL+ cells in the PI group versus controls, reduced by IL-17A neutralization. CONCLUSION: Our findings demonstrate that local IL-17A blockade effectively attenuates peri-implant alveolar bone resorption in T2DM rats by suppressing inflammatory responses and osteoclastogenesis, supporting this targeted strategy as a promising therapeutic approach for diabetic peri-implantitis. However, as these are preclinical results, further studies are needed to validate the therapeutic relevance of this targeted strategy for diabetic peri‑implantitis.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: